Viatris Third Quarter 2026 Financial Results - VIATRIS INC

Explicit Guidance:

• 2026 Full-Year Operational Growth: Midpoint guidance raised to 2% for total revenues, 6% for adjusted EBITDA, and 8% for adjusted EPS (excluding Pacira acquisition impacts).
• 2027 Revenue Outlook: U.S. innovative medicines business (including post-acquisition Pacira) expected to generate over $1 billion in total revenue.
• 2027 Synergies: Combined operations expect to realize >$50 million in annual cost synergies by end of 2028, with potential for additional savings upon full integration.
• Strategic Review Savings: On track to achieve $120 million in net savings from the enterprise-wide strategic review in 2026.
• Leverage Position: Gross leverage exited Q3 at ~2.9x, within the long-term target range of 2.8–3.2x; Pacira acquisition expected to have minimal impact on leverage as it will be funded by excess cash and short-term borrowings.
• Capital Allocation: Continuation of quarterly dividends and opportunistic share buybacks over the next 3–5 years.

Business-Segment Outlook:

• North America: Growth expected to accelerate into the "high single-digit" range for 2026, driven by higher-margin complex generics (specifically estradiol patches, with volumes ~2x prior year) and new injectable launches. Strategy to shift portfolio away from commodity generics.
• Greater China: Q4 2026 expected to see higher policy impact than Q3, leading to growth moderation to "low to mid-single-digit" range in 2027. Continued strength in cardiovascular portfolio and e-commerce channel expected to offset hospital procurement policy headwinds.
• Europe & Emerging Markets: Total revenues for 2026 expected to be flat; 2026 Q4 impacted by ~$100 million in supply disruptions due to NASPIC facility remediation. Underlying demand in Italy and Spain remains healthy.
• Japan: 2026 net sales expected to decline in "low single digits" due to price regulations. Expectation to return to growth in future driven by uptake of Effexor for GAD, Spidea, and the launch of Wacox.
• Innovative Pipeline (2027 Launches):
  • Fast-acting Meloxicam: Anticipated regulatory decision (PDUFA) by December 27, 2026; launch expected early 2027.
  • Zolrele (Pacira): Added to portfolio in Q4 2026; expected to be immediately accretive to 2027 financials.
  • Winlow: Low-dose contraceptive patch launched in U.S. in October 2026.
  • Rizum-V: Approved for presbyopia indication in U.S.
• Pipeline Milestones (H1 2027):
  • Sineramod: Phase 3 Opus 1/2 readouts expected in H1 2027.
  • Ciladogrel: Phase 3 SOSMI data readout expected in H1 2027 (event-driven study).
  • Norelgestromine-only Patch: Data readout expected in H1 2027.
  • NIFICON (IgA Nephropathy): Regulatory decision anticipated in H2 2027 following NDA submission end of 2026.
  • Fast-acting Meloxicam: Labeled for acute pain treatment; focus on non-opioid protocols.

Market and Competitive Outlook:

• HRT Market: Estimated 45 million U.S. women with asymptomatic menopausal symptoms, <30% treated; market expected to grow significantly post-FDA black box warning removal. Company expects to serve 1.5 million women in 2026 and an additional 1 million in 2027 with its patch portfolio.
• GLP-1 Generics: Secured first-to-file status for Wegovy (semaglutide) 25mg tablets; focus on U.S. market differentiation and selective launches elsewhere.
• Generic Competition (Xarelto): Volume-limited generic entry expected in 2030; strategy focuses on extending product life cycle and sustaining value post-generic entry using IP and lifecycle management.
• Supply Constraints: NASPIC facility remediation continues; company actively expanding capacity (24-7 utilization, new packaging lines, geographic expansion) to meet high demand for estradiol patches.
• Pricing Strategy: Evaluating various pricing models for fast-acting meloxicam pending final label; no specific pricing commitment yet.

Macro / Industry Outlook:

• China Policy: Hospital procurement policies causing growth moderation; enforcement variability across provinces prevents precise impact quantification, but Q4 impact expected to exceed Q3.
• Regulatory Environment: FDA engaged in labeling negotiations for fast-acting meloxicam; NDA submission for NIFICON scheduled end of 2026.
• Market Dynamics: Shift in U.S. towards complex, higher-margin generics; removal of HRT black box warnings driving unexpected demand increase.

Strategic Initiatives:

• Pacira Biosciences Acquisition: Tender offer launched Oct 30, 2026; expected to close before end of November 2026.
  • Acquisition Targets: Adds Xarelto (Expirel) and Zolretra (Zolretta) to portfolio; bolsters U.S. non-opioid pain management capabilities.
  • Financial Impact: Transaction accretive to 2027 revenue and adjusted EBITDA immediately; expected to boost U.S. innovative medicines business to >$1B revenue in 2027.
  • Integration: Leverages Pacira's commercial team to maximize fast-acting meloxicam potential; adds R&D talent for PCRx201 (osteoarthritis gene therapy, Phase II Part A readout pending).
• R&D Expansion: Continuing lifecycle management on Rizum-V and Creon (non-CF indications in Europe, decision H1 2027).
• Supply Chain: New Chief Supply Officer (Paul Duffy) to oversee global manufacturing strategy and remediation efforts.

Risks and Headwinds to Outlook:

• Supply Disruptions: Continued impact from NASPIC facility remediation (remediation activities ongoing; OAI classification received) affecting Europe and Emerging Markets (~$100M Q3 impact).
• Regulatory Risks: PDUFA date for fast-acting meloxicam is Dec 27, 2026; any delay or denial impacts 2027 launch.
• Policy Headwinds: Implementation of hospital procurement policies in China may further moderate growth in Q4 2026 and 2027.
• Loss of Exclusivity (LOE): Ametiza (Japan) potential mid-year 2027 loss; Isosulfam Blue (U.S.) full-year 2027 impact.
• Competitive Pressure: Increasing competition on certain key products in 2026; potential generic entry for Xarelto in 2030.
• Caveats: Guidance excludes Pacira contributions; 2027 targets subject to deal close and integration success.

Management Tone on the Future:

• Confidence: High confidence in "sustained growth" phase; management describes 2026 as a "strong finish" with "tremendous momentum" heading into 2027.
• Strategic Shift: Emphasis on moving U.S. portfolio toward "higher margin, higher growth, stickier revenue" complex generics.
• Acquisition Enthusiasm: Viewed as a "significant step forward" to accelerate innovative medicine strategy and maximize non-opioid pain potential.
• Outlook Revision: Actively narrowing guidance ranges and raising midpoints for all key metrics based on Q3 performance and Q4 momentum.
• Long-term View: Management believes they are "well-positioned" to achieve 2030 targets well ahead of schedule, potentially reaching ~$5 billion EBITDA by 2027 (noting this is not official guidance).

Miscellaneous:

• Leadership Transition: Peter McCormick retired as Chief Supply Officer (Nov 1); Paul Duffy appointed new Chief Supply Officer.
• Cash Flow: Free cash flow of $814M in Q3 (inclusive of transaction/restructuring costs); ~$717M returned to shareholders YTD ($300M buybacks + dividends).
• Generic Pipeline: On track for >100 new product approvals in 2026; launching once-monthly aripiprazole injection (first-to-file final FDA approval).